转移性去势抵抗性前列腺癌（mCRPC）

预约门诊

生存率

生存统计数据

转移性去势抵抗性前列腺癌（mCRPC）的中位预期生存期约为三年。这意味着大约一半确诊这种疾病的患者在三年内死亡，而有大约一半的患者存活更长时间。

转移性去势抵抗性前列腺癌不太可能治愈，但可以治疗。得到这一确诊的大多数患者会因这种癌症去世。

根据美国国家癌症研究所的数据，转移性前列腺癌的五年生存率约为 38%。这意味着，每 100 名转移性前列腺癌患者中，预计约有 38 名患者在确诊后五年仍然存活。这一数字既包括癌症对激素治疗敏感的患者，也包括癌症有耐药性的患者。

请记住，被计入癌症生存率的患者均在五年多前确诊。这些患者可能没有接触过最新疗法。请与医护团队讨论您的预后以及可能影响您个人治疗前景的因素。

预后

转移性去势抵抗性前列腺癌患者的预期生存期取决于许多因素。影响预后的因素包括：

  • PSA 水平。 PSA 水平偏高以及 PSA 水平迅速升高会导致预后较差。
  • 癌症扩散部位。 扩散到淋巴结和骨骼的前列腺癌，预后好于扩散到肝脏和肺部等器官的情况。
  • 癌症扩散部位数量。 癌症扩散部位少，预后好于扩散部位多的癌症。
  • 整体健康状况。 如果患者健康状况不佳并伴有其他严重健康状况，则预后较差。
  • 症状。 如果患者需要使用强效止痛药来帮助控制前列腺癌的症状，则预后较差。

要最清晰、最全面地了解您的治疗前景，请咨询医护团队。医护团队了解您的整体健康状况，可以作出更具个性化的预后判断。

申请预约
诊断与治疗医生与科室
April 29, 2026

Living with 转移性去势抵抗性前列腺癌（mCRPC）?

Connect with others like you for support and answers to your questions in the Prostate Cancer support group on Mayo Clinic Connect, a patient community.

Prostate Cancer Discussions

dodgerblue
Intraductal prostate carcinoma: What is standard treatment?

37 Replies Tue, Jul 28, 2026

vcash
Can anyone share their experience with Pluvicto?

286 Replies Fri, Jul 24, 2026

desertrat
Starting Proton Treatments for Prostate Cancer: Any experiences?

227 Replies Mon, Jul 20, 2026

See more discussions
  1. Dmochowski RR, et al., eds. Campbell-Walsh-Wein Urology. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Oct. 2, 2025.
  2. Advanced prostate cancer patient guide. Urology Care Foundation. https://www.urologyhealth.org/educational-resources/advanced-prostate-cancer. Accessed Oct. 2, 2025.
  3. Harris WP, et al. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology. 2009; doi:10.1038/ncpuro1296.
  4. Lowrance W, et al. Advanced prostate cancer: AUA/SUO guideline. https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer. Accessed Oct. 2, 2025.
  5. DeVita VT Jr, et al., eds. Cancer of the prostate. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Oct. 2, 2025.
  6. Harrington LA, et al., eds. Hormones and cancer. In: The Basic Science of Oncology. 6th ed. McGraw Hill; 2021. https://hemonc.mhmedical.com. Accessed Oct. 2, 2025.
  7. Dawson NA, et al. Overview of the treatment of castration-resistant prostate cancer (CRPC). https://www.uptodate.com/contents/search. Accessed Oct. 2, 2025.
  8. Testosterone test. Testing.com. https://www.testing.com/tests/testosterone. Accessed Oct. 10, 2025.
  9. Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1459. Accessed Oct. 2, 2025.
  10. Fact sheet: Molecular imaging and prostate cancer. Society of Nuclear Medicine & Molecular Imaging. https://snmmi.org/Patients/Patients/Fact-Sheets/Molecular-Imaging-and-Prostate-Cancer.aspx. Accessed Oct. 10, 2025.
  11. Garje R, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. Journal of Clinical Oncology. 2025; doi:10.1200/JCO-25-00007.
  12. Targeted therapy to treat cancer. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies. Accessed Oct. 10, 2025.
  13. Abida W, et al. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. https://www.uptodate.com/contents/search. Accessed Oct. 2, 2025.
  14. Gulley J. Immunotherapy for castration-resistant prostate cancer. https://www.uptodate.com/contents/search. Accessed Oct. 2, 2025.
  15. Fact sheet: Radiopharmaceutical therapy and prostate cancer. Society of Nuclear Medicine & Molecular Imaging. https://snmmi.org/Patients/Patients/Fact-Sheets/Radiopharmaceutical-Therapy-and-Prostate-Cancer.aspx. Accessed Oct. 10, 2025.
  16. Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/stereotactic. Accessed Oct. 10, 2025.
  17. Goldman L, et al., eds. Prostate cancer. In: Goldman-Cecil Medicine. 27th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed Oct. 10, 2025.
  18. Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed Oct. 10, 2025.
  19. Choline C 11 injection (approval letter). New Drug Application 203155. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed April 4, 2025.
  20. Harris KM. Allscripts EPSi. Mayo Clinic. April 23, 2024.
  21. Become a comprehensive radiopharmaceutical therapy center of excellence. Society of Nuclear Medicine & Molecular Imaging. https://snmmi.org/Web/Clinical-Practice/Radiopharmaceutical-Therapy-Centers-of-Excellence/Become-a-Comprehensive-Radiopharmaceutical-Therapy-Center-of-Excellence.aspx. Accessed July 29, 2025.
  22. Medical review (expert opinion). Mayo Clinic. Dec. 2, 2025.

相关

相关医疗程序

转移性去势抵抗性前列腺癌（mCRPC）